Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Pfizer Inc (PFE) Price & Performance

ProShares UltraShort Bloomberg Natural Gas ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

ProShares UltraShort Bloomberg Natural Gas ETF vs Pfizer Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.88, while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc pays a 6.36% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and Pfizer Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.

KOLDPFE
Sector
Leveraged / InverseHealth
52-Week High
$49.39$28.56
52-Week Low
$13.58$23.60
Market Cap
$154.18B
Volume
29,869,932
Enterprise Value
$205.67B
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares UltraShort Bloomberg Natural Gas ETF

KOLD, trading at $31.22, is down 2.19% over the past 24 hours. The technical outlook is bullish based on moving averages, with key support at $30 and resistance at $32. Recent news highlights natural gas market volatility, with futures influenced by weather forecasts and LNG export flows. Financial ratios are unavailable in the provided data, limiting fundamental assessment.

The stock's near-term trajectory hinges on natural gas price movements and demand shifts. While technical indicators suggest upward momentum, the lack of fundamental data and exposure to commodity price swings present risks. Investors should weigh the ETF's leveraged structure against market volatility for tactical positioning.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares UltraShort Bloomberg Natural Gas ETF

KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.

Read more on KOLD

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE